For the quarter ended June 2025, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.05 billion, up 2.1% over the same period last year. EPS came in at -$8.25, compared to $5.30 in the year-ago quarter.
The reported revenue represents a surprise of -0.26% over the Zacks Consensus Estimate of $1.05 billion. With the consensus EPS estimate being -$6.12, the EPS surprise was -34.8%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Jazz performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Royalties and contract revenues: $60.14 million versus $55.53 million estimated by 10 analysts on average.
- Revenues- Product sales, net: $985.57 million versus the 10-analyst average estimate of $999.45 million. The reported number represents a year-over-year change of +2.2%.
- Total revenues- Neuroscience- Total: $707.02 million versus $716.27 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +3.3% change.
- Total revenues- Oncology- Total: $274.15 million compared to the $274.32 million average estimate based on nine analysts. The reported number represents a change of -1.1% year over year.
- Total revenues- Oncology- Rylaze/Enrylaze: $100.66 million compared to the $105.31 million average estimate based on nine analysts. The reported number represents a change of -6.7% year over year.
- Total revenues- Neuroscience- Oxybate (Xywav & Xyrem): $450.67 million versus the nine-analyst average estimate of $440.11 million. The reported number represents a year-over-year change of +4.7%.
- Total revenues- Neuroscience- Sativex: $4.62 million compared to the $5.63 million average estimate based on nine analysts. The reported number represents a change of -27.7% year over year.
- Total revenues- Neuroscience- Oxybate- Xyrem: $35.35 million versus the nine-analyst average estimate of $34.64 million. The reported number represents a year-over-year change of -43.2%.
- Total revenues- Oncology- Defitelio/defibrotide: $48.11 million compared to the $47.83 million average estimate based on nine analysts. The reported number represents a change of +5.9% year over year.
- Total revenues- Oncology- Vyxeos: $44.85 million versus $41.48 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +4.3% change.
- Total revenues- Oncology- Zepzelca: $74.54 million versus $77.82 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -8% change.
- Total revenues- Neuroscience- Oxybate- Xywav: $415.32 million versus $405.49 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +12.7% change.
View all Key Company Metrics for Jazz here>>>
Shares of Jazz have returned +7.9% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
